ClinicalTrials.gg
RecruitingNCT07769268HYPERPIGUpdated Sep 16, 2026

Efficacy Evaluation of a Cosmetic Product for Facial Hyperpigmentation

An interventional study of Blancy Pro in Hyperpigmentation and Melasma (Facial Melasma), sponsored by Brainfarma Industria Química e Farmacêutica S/A. Recruiting at 1 site in Brazil. Open to female participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Brainfarma Industria Química e Farmacêutica S/A (part of Hypera Pharma) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
30 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Hyperpigmentation with a site in Brazil — 7 open to participants now, 7 under way, none of them phase 3. Hyperpigmentation · Brazil.

Started
2026
with 3 others
No phase
7 of 10
6 open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
Brainfarma Industria Química e Farmacêutica S/A

Among the 10 studies in Hyperpigmentation with a site in Brazil, this one is one of 4 that started in 2026, is one of 7 with no phase, and was the 9th registered.

Hyperpigmentation

128 studies on the registry are indexed under Hyperpigmentation; 28 are open to participants now.

Browse Hyperpigmentation studies →

Open to participants now

7 of the 10 studies in Hyperpigmentation with a site in Brazil are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 17 Hyperpigmentation studies recruiting now, 9 (53%) set no upper age limit and 8 (47%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 30 Years to 60 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hyperpigmentation with a site in Brazil, or all of them as a file.
02

Study summary

This is a single-center, single-blind clinical study designed to evaluate the efficacy of a depigmenting gel cream through clinical, subjective, and instrumental assessments. A total of 40 female participants, aged 30 to 60 years, will be enrolled and followed for 90 days while using the study product.Participants will be assigned to one of two groups. Group I will include 20 participants with facial hyperpigmentation, including post-inflammatory hyperpigmentation and solar lentigines, representing Fitzpatrick skin phototypes I to VI, with at least one participant from each phototype. Group II will include 20 participants with moderate or greater melasma, as assessed by the modified Melasma Area and Severity Index (mMASI), representing Fitzpatrick skin phototypes II to V.

The study aims to evaluate the product's effectiveness in reducing facial hyperpigmentation and improving skin appearance over the treatment period.

03

Conditions studied

  • Hyperpigmentation
  • Melasma (Facial Melasma)
04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants aged 30 to 60 years.
  • Group I: Participants with Fitzpatrick skin phototypes I to VI, with at least one participant from each phototype category. Participants with facial hyperpigmentation, including post-inflammatory hyperpigmentation and solar lentigines.
  • Group II: Participants with moderate or greater melasma, as assessed by the modified Melasma Area and Severity Index (mMASI), and Fitzpatrick skin phototypes II to V.
  • Willingness to comply with all study procedures and attend scheduled on-site visits and assessments.
  • Willingness to comply with study procedures and be available for remote contact (telehealth) at scheduled times.
  • Ability to understand the study requirements, provide written , and sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study.
  • Use of anti-inflammatory, , or antihistamine medications within 3 weeks prior to screening.
  • Skin conditions or marks in the study area that may interfere with the evaluation of skin reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn.
  • History of atopic conditions or allergy to cosmetic products.
  • Active skin diseases and/or lesions in the assessment area.
  • Immunosuppression due to medication use or active disease.
  • Uncontrolled endocrine disorders.
  • Relevant medical history or current evidence of alcohol or substance abuse.
  • Known history or suspected intolerance to products of the same category as the study product.
  • Intense sun exposure within 15 days prior to assessment.
  • Aesthetic or dermatological treatments within 4 weeks prior to assessment.
  • Any other condition that, in the investigator's opinion, may interfere with study participation or justify exclusion from the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Facial Hyperpigmentation Group

    Female participants aged 30 to 60 years with facial hyperpigmentation, including post-inflammatory hyperpigmentation and solar lentigines, Fitzpatrick skin phototypes I to VI, with at least one participant from each phototype. Participants will use the depigmenting gel cream for 90 days.

    Other: Blancy Pro

  • Experimental
    Melasma Group

    Female participants aged 30 to 60 years with moderate or greater melasma, as assessed by the modified Melasma Area and Severity Index (mMASI), Fitzpatrick skin phototypes II to V. Participants will use the depigmenting gel cream for 90 days.

    Other: Blancy Pro

Interventions

  • OtherBlancy Pro

    Blancy Pro is a depigmenting gel cream intended to reduce facial hyperpigmentation and improve skin appearance. Participants will use the product for 90 days, and efficacy will be assessed through clinical, subjective, and instrumental evaluations.

06

What researchers measure

Primary outcomes

  1. Change in Facial Hyperpigmentation Assessed by Chromameter (L* Parameter)

    Evaluation of the efficacy of the investigational product in improving facial hyperpigmentation in participants with post-inflammatory hyperpigmentation, solar lentigines, and melasma through colorimetric measurements obtained using the Chromameter® device. Changes in the L\* parameter will be assessed over time, with higher values indicating skin lightening.

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

Secondary outcomes

  1. Clinical Improvement of Facial Hyperpigmentation Assessed by a 5-Point Scale

    Evaluation of the efficacy of the investigational product in improving facial hyperpigmentation in participants with post-inflammatory hyperpigmentation, solar lentigines, and melasma through clinical assessment using a 5-point evaluation scale, ranging from 1 (Very Severe) to 5 (Absent). Higher scores indicate less severe pigmentation and a better clinical outcome.

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

  2. Change in Melasma Severity Assessed by the Modified Melasma Area and Severity Index (mMASI)

    Evaluation of the efficacy of the investigational product in improving melasma in participants diagnosed with melasma using the Modified Melasma Area and Severity Index (mMASI). The mMASI assesses melasma severity across four facial regions: forehead, right malar region, left malar region, and chin, weighted according to their proportional facial areas. Scores range from 0 to 24, with 0 indicating no melasma and 24 indicating the most severe melasma. Higher scores indicate worse disease severity, and lower scores indicate improvement. The mMASI score is calculated using the formula: mMASI = 0.3(AF×PF) + 0.3(AMD×PMD) + 0.3(AME×PME) + 0.1(AM×PM).

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

  3. Change in the Number of Facial Pigmented Lesions Assessed by VISIA® Imaging System

    Evaluation of the efficacy of the investigational product in reducing the number of facial pigmented lesions in participants with post-inflammatory hyperpigmentation, solar lentigines, and melasma through image analysis using the VISIA® imaging system (Canfield Software).

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

  4. Change in Facial Skin Tone Uniformity Assessed by VISIA® Image Analysis

    Evaluation of the efficacy of the investigational product in improving facial skin tone uniformity in participants with post-inflammatory hyperpigmentation, solar lentigines, and melasma through image analysis using the VISIA® system and Image-Pro Plus software.

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

  5. Change in Facial Skin Hydration Assessed by Corneometer®

    Evaluation of the ability of the investigational product to improve facial skin hydration in participants with post-inflammatory hyperpigmentation, solar lentigines, and melasma through instrumental measurements obtained using the Corneometer® device.

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

  6. Maintenance of Skin pH Assessed by Skin pHmeter®

    Evaluation of the maintenance of skin pH during use of the investigational product in participants with post-inflammatory hyperpigmentation, solar lentigines, and melasma through instrumental measurements obtained using the Skin pHmeter®.

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

  7. Maintenance of Skin Barrier Function Assessed by Tewameter®

    Evaluation of the maintenance of skin barrier function during use of the investigational product through instrumental measurements of transepidermal water loss (TEWL) using the Tewameter® device.

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

  8. Safety of the Investigational Product Under Normal Conditions of Use

    Evaluation of the safety and tolerability of the investigational product under normal conditions of use in the target population through clinical monitoring of adverse reactions and tolerability assessments.

    Time frame: Day 30, Day 60, and Day 90

  9. Participant-Perceived Efficacy and Product Performance Assessed by Subjective Questionnaire

    Evaluation of the perceived efficacy and performance of the investigational product from the participants' perspective using a Likert Scale questionnaire administered under real-world conditions of use. The Likert Scale ranges from "Strongly Disagree" to "Strongly Agree".

    Time frame: Day 14, Day 30, Day 60, and Day 90

  10. Change in Quality of Life Assessed by the MelasQoL Questionnaire

    Evaluation of the impact of treatment on the quality of life of participants with melasma using the Melasma Quality of Life Scale (MelasQoL). The MelasQoL assesses the impact of melasma on daily life and well-being using ordered response categories ranging from "Not bothered at all" to "Bothered all of the time." Responses indicating less bother reflect better quality of life, while responses indicating greater bother reflect worse quality of life.

    Time frame: Baseline (Day 0), Day 30, Day 60, and Day 90

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No plan has been established to share individual participant data (IPD) collected during this study. Participant confidentiality and privacy will be protected in accordance with applicable regulations and institutional policies.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jan 2027, 6 months after the start.

Of 28 industry-sponsored interventional studies with no phase under Hyperpigmentation, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 7. This study's planned 6 months is above that.

Counting every sponsor, half of 66 studies reached it within 7 months; a quarter within 3 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2026
First posted
Aug 17, 2026
StartActual
Jul 13, 2026
Primary completionEst.
Jan 21, 2027
CompletionEst.
Jan 21, 2027
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07769268
Responsible party
Sponsor
First posted
Aug 17, 2026
Start date
Jul 13, 2026
Primary completion
Jan 21, 2027 (estimated)
Completion
Jan 21, 2027 (estimated)
Last update
Sep 16, 2026

Study contacts

Layane Melody Da Silva Reis Cavalcante
Contact
layane.reis@brainfarma.ind.br
+55 (11) 4507-2183
Sergio Schalka
principal investigator · Grupo Medcin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion